STAT

Opinion: Getting past the bad blood of Theranos through collaboration

The Theranos saga comes with a silver lining — a recognition that liquid biopsies are going to take commitment and collaboration.
Source: Kristoffer Tripplaar/AP

This week’s news that the Securities and Exchange Commission charged Theranos and with fraud put the troubles of the company back into the spotlight. For those of us in the field of liquid biopsy, Theranos has cast a long and persistent shadow on what’s clearly one of the most promising areas in cancer care — using blood tests to improve detection, diagnosis, and treatment and, more broadly, advancing the reality of precision medicine in cancer.

You're reading a preview, sign up to read more.

More from STAT

STAT3 min readPsychology
To Sleep, Perchance To Forget? Scientists Pinpoint In Mice The Neurons That Control Memory While Dreaming
If you wonder why we forget our dreams, new research in mice might answer that question and others related to memory.
STAT4 min read
Opinion: Cokie Roberts: A Beacon For Cancer Survivors Like Me
In full view of her ABC News audience and on the air at NPR, Cokie Roberts lived publicly with breast cancer for 17 years. That's a victory, even if she…
STAT3 min read
Opinion: Why Didn’t Nonprofits And The NIH Require ‘Reasonable’ Pricing For Zolgensma? That May Happen In France
U.S. tax-exempt charities and the NIH should insist on reasonable pricing agreements for the medicines they help make. It's crazy that they don't.